Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 118 publications
ASO Visual Abstract: Accuracy of Index Lymph Node Pathology in Predicting Overall Response to Neoadjuvant Immunotherapy for Clinical Stage III Melanoma-Results from the Prospective NeoACTIVATE Arm C (NCT03554083) Substudy.
Journal: Annals of surgical oncology
Published: June 17, 2026
ASO Author Reflections: When Is the Index Lymph Node Not Enough?
Journal: Annals of surgical oncology
Published: May 27, 2026
Real-World Treatment Patterns in Advanced Cutaneous Melanoma in the USA.
Journal: Targeted oncology
Published: May 16, 2026
Real-World Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma: Treatment Delivery, Immune Reconstitution, and Cardiac Monitoring During High-Dose IL-2.
Journal: Current oncology (Toronto, Ont.)
Published: May 07, 2026
Prehabilitation during neoadjuvant chemotherapy in advanced ovarian cancer is associated with improved surgical candidacy and chemotherapy outcomes.
Journal: Gynecologic oncology
Published: May 05, 2026
Serum Interleukin-6 Levels in Endometriosis and Endometriosis-Associated Ovarian Cancer: A Systematic Review and Meta-Analysis Demonstrating a Biological Gradient.
Journal: Journal of minimally invasive gynecology
Published: April 17, 2026
Long-Term Survival in High-Grade Serous Ovarian Cancer Compared With the General US Population: A 30-Year Landmark Analysis.
Journal: JCO oncology advances
Published: April 01, 2026
Accuracy of Index Lymph Node Pathology in Predicting Overall Response to Neoadjuvant Immunotherapy for Clinical Stage III Melanoma: Results From the Prospective NeoACTIVATE Arm C (NCT03554083) Substudy.
Journal: Annals of surgical oncology
Published: February 24, 2026
Clinical and Radiometabolic Correlatives of ddPCR Liquid Biopsy for BRAF V600 Mutated Melanoma.
Journal: International journal of cancer
Published: October 23, 2025
Biomarker analysis of circulating tumor DNA in clinical stage III melanoma patients treated with neoadjuvant immunotherapy combined with targeted therapy.
Journal: Therapeutic advances in medical oncology
Published: September 11, 2025
A Phase 2 Trial of Protein Kinase C Iota Inhibition With the Combination of Auranofin and Sirolimus in Patients With Recurrent Ovarian Cancer.
Journal: American journal of clinical oncology
Published: September 08, 2025
ASO Author Reflections: Is PET/CT Response Assessment After Neoadjuvant Systemic Therapy for Stage III Melanoma Enough?
Journal: Annals of surgical oncology
Published: August 13, 2025
Last Updated: 09/26/2026